Introduction
============

Bladder cancer is the sixth most common cause of cancer mortality and its incidence has increased markedly in recent decades ([@b1-ol-0-0-10706],[@b2-ol-0-0-10706]) as well as an increasing prevalence of established risk factors such as smoking, overweight, physical inactivity, and changing reproductive patterns associated with urbanization and economic development. Based on GLOBOCAN estimates, about 14.1 million new cancer cases and 8.2 million deaths occurred in 2012 worldwide. Over the years, the burden has shifted to less developed countries, which currently account for about 57% of cases and 65% of cancer deaths worldwide. Lung cancer is the leading cause of cancer death among males in both more and less developed countries, and has surpassed breast cancer as the leading cause of cancer death among females in more developed countries; breast cancer remains the leading cause of cancer death among females in less developed countries. Other leading causes of cancer death in more developed countries include colorectal cancer among males and females and prostate cancer among males. In less developed countries, liver and stomach cancer among males and cervical cancer among females are also leading causes of cancer death. Although incidence rates for all cancers combined are nearly twice as high in more developed than in less developed countries in both males and females, mortality rates are only 8 to 15% higher in more developed countries. This disparity reflects regional differences in the mix of cancers, which is affected by risk factors and detection practices, and/or the availability of treatment. Risk factors associated with the leading causes of cancer death include tobacco use (lung, colorectal, stomach, and liver cancer. Current prognostic factors, namely TNM stage and pathological grade, insufficiently predict outcome at the individual level. The different outcome for patients with the same stage and grade calls for new prognostic molecular markers that may also serve as therapeutic targets.

Several high-throughput studies have focused on delineating genomic changes and gene expression in the various stages of bladder-cancer development and progression. Recent genomic analyses, part of The Cancer Genome Atlas, have identified several new target genes not previously described in bladder carcinogenesis ([@b3-ol-0-0-10706]--[@b6-ol-0-0-10706]).

Pleckstrin homology domain-containing S1 (*PLEKHS1*) is one of the most remarkable targets, because after telomerase reverse transcriptase (*TERT*), it is the second gene of the human genome showing frequent somatic non-coding mutations within its promoter ([@b7-ol-0-0-10706]). This gene, located on chromosome 10q25.3, encodes the PLEKHS1 protein with unknown function. These mutations are single-nucleotide substitutions in the *PLEKHS1* proximal promoter (in intron 1 with a non-coding exon 1 from NM_024889.4): *substitutions* that effect guanine at position Chr.10: 115511590 and cytosine at position Chr.10: 115511593 from the GRCh37 *(hg19)* genomic coordinate (or c.-20+70G and c.-20+73C from NM_024889.4). These mutations are close to the translation start site of the *PLEKHS1* gene (−3,447 and −3,444 bp upstream of the translation start site) and are flanked by stretches of 10 bp on both sides that are palindromic to each other. The two *PLEKHS1* promoter mutations could be considered among the most common noncoding mutations in cancer. In bladder cancer, almost 40% of tumors could be affected by promoter mutations of this gene ([@b8-ol-0-0-10706]). However, data on messenger ribonucleic acid (mRNA) expression levels in bladder cancer are still lacking.

We analyzed the frequency of promoter mutations and mRNA expression of PLEKHS1 in two large series of 335 bladder tumors: 162 non-muscle-invasive bladder cancer (NMIBC) (71 and 91, respectively) and 173 muscle-invasive bladder cancers (MIBC) (83 and 90, respectively). A retrospective review of patient outcomes allowed for performing survival analyses to highlight the putative prognostic value of this gene.

Patients and methods
====================

### Patients and samples

We analyzed samples from two series of patients with urothelial carcinoma of the bladder. The first series consisted of 154 patients who had undergone transurethral bladder resection or a radical cystectomy in our hospital between 2002 and 2007. Immediately after surgery, tumor samples from each patient were frozen in liquid nitrogen and stored at −80°C \[for DNA (deoxyribonucleic acid) and RNA extraction\] and fixed in formaldehyde. Specimens of normal bladder tissue from 20 patients undergoing surgery unrelated to bladder tumors (transurethral resection of the prostate, prostatic adenomectomy) were used as sources of normal bladder tissues.

Each tumor was reviewed by two pathologists (DD and MS) who were blinded to the clinical outcomes. Tumors were re-staged according to the 2009 TNM classification of bladder tumors ([@b9-ol-0-0-10706]) and were graded according to the WHO 2004 tumor-grading scheme ([@b10-ol-0-0-10706]). Standard follow-up visits followed current guidelines.

The second series was collected from 181 patients treated surgically between 1988 and 2006 at Henri Mondor Hospital, Institut Gustave Roussy (Villejuif, France) and Foch Hospital (Suresnes, France). Pure SCC and pure adenocarcinoma were excluded. Immediately after surgery, tumor samples from each patient were frozen in liquid nitrogen and stored at −80°C (for DNA and RNA extraction) and fixed in formaldehyde. For non muscle invasive cases (stage Ta or T1), TURB material was used; for muscle invasive cases, TURB or cystectomy material was used, without prior neoadjuvant chemotherapy, as previously described in Rebouissou *et al* ([@b11-ol-0-0-10706]).

All patients provided written informed consent. These studies received approval from an institutional review board, Centre d\'Éthique Clinique de l\'Hôpital Cochin, and was conducted according to the principles outlined in the Declaration of Helsinki.

### DNA mutation analysis

*PLEKHS1* has two mutational spots that are well described. The assessment was performed by a screening with high-resolution melt (HRM) analysis followed by Sanger sequencing of samples with a mutated profile on HRM to validate the HRM data and determine the nomenclature of mutations found. The nucleotide sequences for the primers were for *PLEKHS1*-U (5′-CTTCCAAGGCTGGGATGATCTA-3′) and *PLEKHS1*-L (5′-AAGAAAGTGCCCATAACAGAAATACA-3′) (polymerase chain reaction (PCR) product of 107 bp).

### Real-time RT-qPCR

The theoretical basis, primers and PCR consumables, RNA extraction, complementary deoxyribonucleic acid (cDNA) synthesis, and PCR-reaction conditions were previously described in detail ([@b12-ol-0-0-10706]). One endogenous RNA control gene was chosen, namely *TBP* (GenBank accession no. NM_003194), which encodes the TATA box-binding protein. Because *PLEKHS1* was expressed in tumor samples but not normal bladder tissue, values were normalized so that a Ct value of 35 was set to 1. Taking into account the optimal cut-off for *PLEKHS1*, mRNA values ≥100 were considered overexpression.

Primers were chosen with the assistance of the Oligo 6.0 computer program (National Biosciences, Plymouth, MN). The nucleotide primer sequences were *PLEKHS1*-U (5′-AAGATGTTTAAATGCCACCCTGATG-3′) and *PLEKHS1*-L (5′-CCAGTCTTTAATCTTCTCCCTGTCGT-3′) (PCR product of 99 bp). Experiments were performed in duplicate for each data point.

### Statistical analysis

The clinicopathologic features of NMIBC and MIBC were tested for their association with tumor recurrence and survival by Student\'s t-test for continuous variables or χ^2^ test for qualitative variables. The distribution of mRNA levels was described with medians (range). Relationships between clinical and histological variables and mRNA levels of *PLEKHS1* were tested by the non-parametric Mann-Whitney U test and Kruskal-Wallis H-test. Overall survival (OS) was calculated from the date of surgery until death or the last follow-up. Recurrence-free survival (RFS) was defined as the time from the date of surgery to the first local relapse or first metastasis. For NMIBC, progression-free survival (PFS) was defined as the time from the date of surgery to progression to muscle-invasive disease. Survival curves were derived from Kaplan-Meier estimates. The log-rank test was used to compare survival between subgroups. The prognostic impact of mRNA levels, adjusted for the other prognostic factors, was assessed by Cox proportional-hazards regression analysis, estimating hazard ratios and 95% confidence intervals. The variables significant in univariate analysis (P\<0.10) were included in multivariate analysis. Differences were considered significant at P\<0.05.

Results
=======

### Clinicopathologic characteristics of the cohorts

Complete clinical, histological and survival data were obtained from medical records for these 154 patients \[129 men and 25 women; median age 70 years (range, 31--91)\]. Pathological staging showed NMIBC in 71 patients (25 low-grade pTa, 17 high-grade pTa, 29 high-grade pT1) and high-grade MIBC in 83 patients. For NMIBC, the median follow-up was 57.4 months (range, 1--158 months; mean follow-up, 61 months). For MIBC, the median follow-up was 12.5 months (range, 1--152 months; mean follow-up, 29 months). In the MIBC cohort, 12 patients (14.5%) received neoadjuvant chemotherapy before cystectomy and 25 (30.1%) received adjuvant chemotherapy taking into account pathological characteristics of the tumor and renal function. Clinical, histological and survival characteristics for the first series are presented in [Tables I](#tI-ol-0-0-10706){ref-type="table"} and [II](#tII-ol-0-0-10706){ref-type="table"}.

The second series consisted of an independent cohort of 181 patients with bladder cancer \[150 men and 31 women; median age 67 years (range, 30--95)\]. Pathological staging showed NMIBC in 91 patients (33 low-grade pTa, 17 high-grade pTa, 41 high-grade pT1) and high-grade MIBC in 90 patients. In this second cohort, molecular subgroups (basal phenotype, called MC7, vs non-basal phenotype) were previously determined by using the CIT (Carte d\'Identité des Tumeurs) classification ([@b11-ol-0-0-10706]) we identified an MIBC subgroup accounting for 23.5% of MIBC, associated with shorter survival and displaying a basal-like phenotype, as shown by the expression of epithelial basal cell markers. Basal-like tumors presented an activation of the epidermal growth factor receptor (EGFR). None patient of the second cohort received neoadjuvant chemotherapy. As in the first cohort, patients received adjuvant chemotherapy taking into account pathological characteristics of the tumor if they were eligible. Clinical and histological variables did not differ between the two series, except for history of NMIBC ([Table III](#tIII-ol-0-0-10706){ref-type="table"}).

### DNA mutations of PLEKHS1

DNA mutation analysis involved 103 available tumor DNA samples (44 NMIBC and 59 MIBC) from the first series and 18 normal bladder samples, then the 181 tumor samples (91 NMIBC and 90 MIBC) from the second series.

In the first series, 11/44 NMIBC (25.0%) and 19/59 MIBC (32.2%) samples had a promoter-mutated profile ([Table IV](#tIV-ol-0-0-10706){ref-type="table"}). The *PLEKHS1* promoter exhibited recurrent mutations at two genomic positions: c.-20+70 (G\>A and G\>C) and c.-20+73 (C\>A, C\>T and C\>G). NMIBC and MIBC samples did not differ by type of mutation (P=0.43).

In the second series, 30/91 NMIBC (33.0%) and 34/90 MIBC (37.8%) samples had a promoter-mutated profile ([Table IV](#tIV-ol-0-0-10706){ref-type="table"}). The DNA-mutated profile was not significantly associated with clinical parameters for patients with NMIBC ([Table V](#tV-ol-0-0-10706){ref-type="table"}) or MIBC ([Table VI](#tVI-ol-0-0-10706){ref-type="table"}). Regarding molecular subgroups in MIBC, a DNA-mutated profile was significantly more frequent with the basal phenotype (MC7) than the non-basal phenotype (61.5 vs. 27.1%, P=0.0025). PLEKHS1 DNA mutation was not associated with prognosis, in terms of recurrence or progression with NMIBC and in terms of RFS or OS with MIBC (data not shown).

### mRNA expression of PLEKHS1

The mRNA expression of *PLEKHS1* was assessed in the first series (n=154). The median mRNA *PLEKHS1* level was 19.7 \[range, 0.0--972.6\] with NMIBC and 25.7 \[0.0--2288.1\] with MIBC, vs. 0.0 \[0.0--21.4\] in normal bladder samples. *PLEKHS1* was overexpressed in NMIBC and MIBC versus normal bladder tissue (P=0.00031 and P=0.000025), with no difference in level between NMIBC and MIBC (P=0.51). Overall, 22.5 and 27.7% of NMIBC and MIBC tumors showed *PLEKHS1* overexpression (vs. 0% in normal bladder samples, P\<0.01). *PLEKHS1* mRNA level was not associated with DNA mutations in NMIBC (P=0.39) or MIBC (P=0.84).

### Prognostic value of PLEKHS1 mRNA overexpression

*PLEKHS1* mRNA overexpression was not significantly associated with clinical variables in NMIBC ([Table VII](#tVII-ol-0-0-10706){ref-type="table"}) or MIBC ([Table VIII](#tVIII-ol-0-0-10706){ref-type="table"}). With NMIBC, *PLEKHS1* overexpression was associated with worse PFS on univariate analysis (P=0.0069) ([Fig. 1](#f1-ol-0-0-10706){ref-type="fig"}). Five- and 10-year PFS rates were 72.4 and 38.8% with *PLEKHS1* overexpression versus 88.9 and 88.7% without *PLEKHS1* overexpression. Other clinical variables affecting PFS on univariate analysis with P\<0.10 on log-rank test included T stage and grade and were retained for multivariate analysis. On multivariate analysis, *PLEKHS1* overexpression remained an independent prognostic factor of PFS (P=0.034) ([Table IX](#tIX-ol-0-0-10706){ref-type="table"}).

Overall, 21/28 patients (75%) who received Bacillus Calmette-Guerin (BCG) therapy showed recurrent NMIBC or progression to an invasive tumor during follow-up, including 15 (53.6%) within the first 2 years. The median *PLEKHS1* mRNA level was higher but not significantly with BCG-refractory tumor or early recurrence (\<24 months) than for BCG responders (no recurrence or \>24 months): 40.8 \[range, 0.0--375.5\] vs. 15.2 \[0.6--381.6\] (P=0.80).

With MIBC, *PLEKHS1* overexpression was not associated with RFS or OS (P=0.33 and P=0.057, respectively).

Discussion
==========

Mutations of *PLEKHS1* are non-coding and are located in the gene promoter and therefore cannot be detected by whole-exome analyses. This is also the case for non-coding mutations located on the upstream regulatory sequences for genes such as *TERT*, WD repeat domain 74 (*WDR74*) and succinate dehydrogenase complex subunit D (*SDHD*) ([@b8-ol-0-0-10706]). Point mutations in the *TERT* promoter are the best known and occur in a subset of tumors with clinical interest. In bladder urothelial carcinomas, almost two thirds of tumors show somatic test mutations ([@b13-ol-0-0-10706]).

To our knowledge, this is the first study to assess PLEKHS1 DNA mutations and mRNA expression in bladder cancer. This assessment is of outmost importance because the association of gene expression and the prognostic impact of promoter mutations in the cancer remain unknown. Whole-genome sequencing of non-coding somatic mutations, rather than these exome studies, might provide answers to these deliberations.

We investigated DNA mutations and mRNA expression in a large series of 154 bladder cancer cases. The results of DNA analysis were then validated in an independent second series (n=181). In these two series, tumors were half non-muscle invasive and half muscle invasive. Characteristics of both populations are consistent with urothelial carcinoma presentation. Moreover, we observed the classical prognostic factors (TNM stage and grade).

We showed a high frequency of promoter DNA mutations for *PLEKHS1*, detected in about one-third of bladder tumors (NMIBC and MIBC). Our results are consistent with the princeps study of Weinhold *et al* describing *PLEKHS1* DNA mutations in 8/20 samples (40%) of bladder cancer ([@b8-ol-0-0-10706]). This high rate of DNA mutations supports the concept of an essential involvement of this gene in bladder carcinogenesis, possibly similar to human *TERT*. It is also of interest as a biomarker to detect circulating tumor DNA that can be used for a variety of clinical and research purposes for bladder cancer.

In our study, *PLEKHS1* mutations were particularly frequent with the basal MIBC phenotype, which is known to have poor prognosis but is associated with improved survival after neoadjuvant chemotherapy ([@b14-ol-0-0-10706]). Further research is needed to assess the role of *PLEKHS1* in the chemosensitivity of MIBC.

*PLEKHS1* mRNA was overexpressed in approximatively one-quarter of bladder tumors, regardless of stage and grade. As well, the expression was particularly high in some tumor samples, but normal bladder tissue showed very low levels.

Although the rates of mutations appear to be almost the same as the proportion of mRNA overexpression, we did not find an association between DNA alterations and mRNA expression. This is an unexpected result suggesting that mutations in the *PLEKHS1* promoter probably do not affect transcription and are not responsible for the increased mRNA expression in our bladder tumor series. Our results disagree with those of Weinhold *et al*., who showed *PLEKHS1* mutations inversely correlated with mRNA expression level in a small series of 20 bladder tumors ([@b8-ol-0-0-10706]). In contrast, somatic mutations in the TERT promoter increased the expression of telomerase ([@b13-ol-0-0-10706]).

In NMIBC, *PLEKHS1* overexpression was associated with poor prognosis and increased risk of progression to muscle-invasive disease. The overexpression remained an independent prognostic factor on multivariate analysis, which is quite remarkable. Indeed, except for TNM stage and pathological grade, we have no molecular markers to distinguish tumors that would be able to progress in muscle-invasive disease during follow-up. This is especially crucial for pT1 high-grade tumors, which have been shown to progress in 30 to 50% of cases during the first 5 years. Early identification of patients at risk of disease progression may lead to more aggressive therapeutic strategies, such as early cystectomy. One of the main issues is the potential response of these tumors to BCG therapy. In our series, even though *PLEKHS1* mRNA expression was three times higher with early recurrent or refractory tumor than other tumors, *PLEKHS1* was not a significant predictive factor of response to BCG therapy. However, the small number of patients who received BCG may explain the lack of statistical power in our study.

One limitation of our study is that a longer follow-up or a larger cohort of patients may be needed to show significance, especially for pT1 tumors and response to BCG. To confirm these data, prospective clinical studies associated with a molecular evaluation of tumors are needed. We tried to assess protein expression by western blot analysis and immunohistochemistry, but the two primary anti-PLEKHS1 antibodies used (i.e., HPA037583, Sigma and H00079949-T01, Abnova) showed no specific protein bands on western blot analysis or on immunostaining (data not shown), which suggests no qualitative antibody available for PLEKHS1. Functional analyses should probably be done in parallel to investigate the role of *PLEKHS1* in carcinogenesis. Recently, Grossmann et al. identified an interaction between PIK3R3 (p55c regulatory subunit of PI3 kinase) and PLEKHS1 ([@b15-ol-0-0-10706]), but the significance of this protein interaction remains uncertain. In our series, even if *PLEKHS1* mutations were significantly more frequent with the basal than non-basal MIBC phenotype, we did not identify any other associated gene or pathway alterations. Therefore, despite its prognostic value, *PLEKHS1* cannot be considered a therapeutic target at this time.

Our results support the involvement of *PLEKHS1* in bladder carcinogenesis. DNA mutations were observed in almost one-third of bladder cancers and approximately one quarter of NMIBC and MIBC tumors showed mRNA overexpression. In MIBC, *PLEKHS1* mutations seem frequent with the basal phenotype. In NMIBC, *PLEKHS1* overexpression may be an independent prognostic factor of progression to muscle-invasive disease. Our study has many biases since it is a retrospective clinical study, small cohort and can only be considered as a preliminary study. The clinical interest remains to be demonstrated by a prospective study centered on high grade NMIBC. Further studies are needed to dissect the mechanisms of action and the specific role of *PLEKHS1* in bladder carcinogenesis and to develop therapeutic inhibitors.
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![Progression-free survival with non-muscle-invasive bladder cancer by *PLEKHS1* mRNA expression. *PLEKHS1*, pleckstrin homology domain-containing S1.](ol-18-04-3471-g00){#f1-ol-0-0-10706}

###### 

Clinical, pathological and survival characteristics of the 71 NMIBC of the first series.

                                               Recurrence   Muscle-invasive progression                
  ------------------ ------------ ------------ ------------ ----------------------------- ------------ --------
  Total population   71 (100.0)   25 (35.2)    36 (50.7)                                  10 (14.1)    
  Age (years)                                                                                          0.08
    ≥60              56 (78.9)    19 (76.0)    27 (75.0)    0.93                          10 (100.0)   
    \<60             15 (21.1)    6 (24.0)     9 (25.0)                                   0 (0.0)      
  Sex                                                                                                  
    Male             63 (88.7)    22 (88.0)    32 (88.9)    0.91                          9 (90.0)     0.89
    Female           8 (11.3)     3 (12.0)     4 (11.1)                                   1 (10.0)     
  Smoking status                                                                                       
    Non-smoker       33 (46.5)    13 (52.0)    15 (41.7)    0.43                          5 (50.0)     0.81
    Smoker           38 (53.5)    12 (48.0)    21 (58.3)                                  5 (50.0)     
  History of NMIBC                                                                                     
    No               39 (54.9)    22 (88.0)    13 (36.1)    \<0.0001                      4 (40.0)     0.31
    Yes              32 (45.1)    3 (12.0)     23 (63.9)                                  6 (60.0)     
  Associated pTis                                                                                      
    No               69 (97.2)    25 (100.0)   36 (100.0)   0.99                          8 (80.0)     0.0004
    Yes              2 (2.8)      0 (0.0)      0 (0.0)                                    2 (20.0)     
  Grade                                                                                                
    Low              25 (35.2)    10 (40.0)    14 (38.9)    0.93                          1 (10.0)     0.07
    High             46 (64.8)    15 (60.0)    22 (61.1)                                  9 (90.0)     
  Tumor stage                                                                                          
    Ta               42 (59.2)    15 (60.0)    24 (66.7)    0.59                          3 (30.0)     0.043
    T1               29 (40.8)    10 (40.0)    12 (33.3)                                  7 (70.0)     

χ^2^ test (recurrence vs no recurrence)

χ^2^ test (muscle-invasive progression vs. others). NMIBC, non-muscle-invasive bladder cancer.

###### 

Clinical, pathological and survival characteristics of the 83 muscle-invasive bladder cancer of the first series.

                                   Disease-free survival   Overall survival               
  ------------------- ------------ ----------------------- ------------------ ----------- --------
  Total population    83 (100.0)   48 (57.8)                                  46 (55.4)   
  Age (years)                                                                             
    ≥60               61 (73.5)    40 (65.5)               0.017              39 (63.9)   0.009
    \<60              22 (26.5)    8 (36.4)                                   7 (31.8)    
  Sex                                                                                     
    Male              66 (79.5)    36 (54.5)               0.23               38 (57.6)   0.44
    Female            17 (20.5)    12 (70.6)                                  8 (47.1)    
  Smoking status                                                                          
    Non-smoker        34 (41.0)    18 (52.9)               0.45               12 (35.3)   0.002
    Smoker            49 (59.0)    30 (61.2)                                  34 (69.4)   
  History of NMIBC                                                                        
    No                59 (71.1)    30 (50.8)               0.043              31 (52.5)   0.41
    Yes               24 (28.9)    18 (75.0)                                  15 (62.5)   
  Associated pTis                                                                         
    No                73 (88.0)    43 (58.9)               0.59               40 (54.8)   0.76
    Yes               10 (12.0)    5 (50.0)                                   6 (60.0)    
  Tumor stage                                                                             
    T2                34 (41.0)    17 (50.0)               0.10               13 (38.2)   0.009
    ≥T3               49 (59.0)    31 (63.3)                                  33 (67.3)   
  Lymph node status                                                                       
    N−                58 (69.9)    27 (46.6)               0.002              25 (43.1)   0.0006
    N+                25 (30.1)    21 (84.0)                                  21 (84.0)   

First recurrence (local or metastatic)

Death

χ^2^ test. NMIBC, non-muscle-invasive bladder cancer.

###### 

Clinical and pathological characteristics of NMIBC and MIBC the two series.

  A, NMIBC                                                                                                                                              
  ------------------------------------------------------------------ ----------------------------- ------------------------- -------------------------- ------------------------------------------------------------
  Total population                                                   162 (100.0)                   71 (100.0)                91 (100.0)                 
  Age (years)^[a](#tfn6-ol-0-0-10706){ref-type="table-fn"}^                                                                                             
    ≥60                                                              108 (72.0)                    56 (78.9)                 52 (65.8)                  0.08
    \<60                                                             42 (28.0)                     15 (21.1)                 27 (34.2)                  
  Sex                                                                                                                                                   
    Male                                                             138 (85.2)                    63 (88.7)                 75 (82.4)                  0.26
    Female                                                           24 (14.8)                     8 (11.3)                  16 (17.6)                  
  History of NMIBC^[b](#tfn7-ol-0-0-10706){ref-type="table-fn"}^                                                                                        
    No                                                               108 (71.5)                    39 (54.9)                 69 (86.3)                  \<0.0001
    Yes                                                              43 (28.5)                     32 (45.1)                 11 (13.7)                  
  Associated pTis^[c](#tfn8-ol-0-0-10706){ref-type="table-fn"}^                                                                                         
    No                                                               134 (93.7)                    69 (97.2)                 65 (90.3)                  0.09
    Yes                                                              9 (6.3)                       2 (2.8)                   7 (9.7)                    
  Grade                                                                                                                                                 
    Low                                                              58 (35.8)                     25 (35.2)                 33 (36.3)                  0.89
    High                                                             104 (64.2)                    46 (64.8)                 58 (63.7)                  
  Tumor stage                                                                                                                                           
    Ta                                                               92 (56.8)                     42 (59.2)                 50 (54.9)                  0.59
    T1                                                               70 (43.2)                     29 (40.8)                 41 (45.1)                  
                                                                                                                                                        
  **B, MIBC**                                                                                                                                           
                                                                                                                                                        
  **Characteristic**                                                 **Whole population, n (%)**   **First series, n (%)**   **Second series, n (%)**   **P-value^[h](#tfn13-ol-0-0-10706){ref-type="table-fn"}^**
                                                                                                                                                        
  Total population                                                   173 (100.0)                   83 (100.0)                90 (100.0)                 
  Age (years)^[d](#tfn9-ol-0-0-10706){ref-type="table-fn"}^                                                                                             
    ≥60                                                              124 (73.8)                    61 (73.5)                 63 (74.1)                  0.93
    \<60                                                             44 (26.6)                     22 (26.5)                 22 (25.9)                  
  Sex                                                                                                                                                   
    Male                                                             141 (81.5)                    66 (79.5)                 75 (83.3)                  0.52
    Female                                                           32 (18.5)                     17 (20.5)                 15 (16.7)                  
  History of NMIBC^[e](#tfn10-ol-0-0-10706){ref-type="table-fn"}^                                                                                       
    No                                                               135 (84.4)                    73 (88.0)                 62 (80.5)                  0.20
    Yes                                                              25 (15.6)                     10 (12.0)                 15 (19.5)                  
  Associated pTis^[f](#tfn11-ol-0-0-10706){ref-type="table-fn"}^                                                                                        
    No                                                               135 (84.4)                    73 (88.0)                 62 (80.5)                  0.20
    Yes                                                              25 (15.6)                     10 (12.0)                 15 (19.5)                  
  Tumor stage                                                                                                                                           
    T2                                                               66 (38.2)                     34 (41.0)                 32 (35.6)                  0.46
    ≥T3                                                              107 (61.8)                    49 (59.0)                 58 (64.4)                  
  Lymph node status^[g](#tfn12-ol-0-0-10706){ref-type="table-fn"}^                                                                                      
    N^−^                                                             93 (63.7)                     58 (69.9)                 35 (55.6)                  0.07
    N^+^                                                             53 (36.3)                     25 (30.1)                 28 (44.4)                  

Data available for 79 patients

data available for 80 patients

data available for 72 patients, in the second series

data available for 85 patients

data available for 83 patients

data available for 77 patients

data available for 63 patients, in the second series.

χ^2^ test. NMIBC, non-muscle-invasive bladder cancer; MIBC, muscle-invasive bladder cancer.

###### 

Frequency of mutations in the *PLEKHS1* promoter in the two series.

               First series (n=103)   Second series (n=181)                                   
  ------------ ---------------------- ----------------------- ------ ----------- ------------ ------
  All tumors   30 (29.1)              73 (70.9)                      64 (35.4)   117 (64.4)   
  NMIBC        11 (25.0)              33 (75.0)               0.43   30 (33.0)   61 (67.0)    0.50
  MIBC         19 (32.2)              40 (67.8)                      34 (37.8)   56 (62.2)    

χ^2^ test. *PLEKHS1*, pleckstrin homology domain-containing S1; NMIBC, non-muscle-invasive bladder cancer; MIBC, muscle-invasive bladder cancer.

###### 

Association of clinicopathological variables and *PLEKHS1* DNA mutated profile with NMIBC from the second series.

  Characteristic                                                    Total population, n (%)   *PLEKHS1* mutated, n (%)   Not mutated, n (%)   P-value^[a](#tfn15-ol-0-0-10706){ref-type="table-fn"}^
  ----------------------------------------------------------------- ------------------------- -------------------------- -------------------- --------------------------------------------------------
  Total                                                             91 (100.0)                30 (33.0)                  61 (67.0)            
  Age (years)^[b](#tfn16-ol-0-0-10706){ref-type="table-fn"}^                                                                                  
    ≥60                                                             52 (65.8)                 17 (32.7)                  35 (67.3)            0.95
    \<60                                                            27 (34.2)                 9 (33.3)                   18 (66.7)            
  Sex                                                                                                                                         
    Male                                                            75 (82.4)                 26 (35.1)                  48 (64.9)            0.74
    Female                                                          16 (17.6)                 4 (26.7)                   11 (73.3)            
  History of NMIBC^[c](#tfn17-ol-0-0-10706){ref-type="table-fn"}^                                                                             
    No                                                              69 (86.3)                 26 (37.7)                  43 (62.3)            0.36
    Yes                                                             11 (13.7)                 2 (18.2)                   9 (81.8)             
  Associated pTis^[d](#tfn18-ol-0-0-10706){ref-type="table-fn"}^                                                                              
    No                                                              65 (90.3)                 21 (32.3)                  44 (67.7)            0.37
    Yes                                                             7 (9.7)                   4 (57.1)                   3 (42.9)             
  Grade                                                                                                                                       
    Low                                                             33 (36.3)                 7 (21.2)                   26 (78.8)            0.098
    High                                                            58 (63.7)                 21 (38.2)                  34 (61.8)            
  Tumor stage                                                                                                                                 
    Ta                                                              50 (54.9)                 14 (28.0)                  36 (72.0)            0.27
    T1                                                              41 (45.1)                 16 (39.0)                  25 (61.0)            
  Phenotype^[e](#tfn19-ol-0-0-10706){ref-type="table-fn"}^                                                                                    
    Basal                                                           1 (1.3)                   0 (0.0)                    1 (100.0)            0.76
    Non-basal                                                       78 (98.7)                 26 (33.3)                  52 (66.7)            

χ^2^ test.

Data available for 79 patients

data available for 80 patients

data available for 72 patients

data available for 79 patients. *PLEKHS1*, pleckstrin homology domain-containing S1; NMIBC, non-muscle-invasive bladder cancer.

###### 

Association of clinicopathological variables and *PLEKHS1* DNA mutated profile with MIBC from the second series.

  Characteristic                                                     Total population, n (%)   *PLEKHS1* mutated, n (%)   Not mutated, n (%)   P-value^[a](#tfn20-ol-0-0-10706){ref-type="table-fn"}^
  ------------------------------------------------------------------ ------------------------- -------------------------- -------------------- --------------------------------------------------------
  Total                                                              90 (100)                  34 (64.8)                  56 (35.2)            
  Age^[b](#tfn21-ol-0-0-10706){ref-type="table-fn"}^                                                                                           
    ≥60                                                              63 (74.1)                 26 (41.3)                  37 (58.7)            0.24
    \>60                                                             22 (25.9)                 6 (27.3)                   16 (72.7)            
  Sex                                                                                                                                          
    Male                                                             75 (83.3)                 29 (38.7)                  46 (61.3)            0.70
    Female                                                           15 (16.7)                 5 (33.3)                   10 (66.7)            
  History of NMIBC^[c](#tfn22-ol-0-0-10706){ref-type="table-fn"}^                                                                              
    No                                                               71 (85.5)                 26 (36.6)                  45 (63.4)            0.38
    Yes                                                              12 (14.5)                 6 (50.0)                   6 (50.0)             
  Associated pTis^[d](#tfn23-ol-0-0-10706){ref-type="table-fn"}^                                                                               
    No                                                               62 (80.5)                 25 (40.3)                  37 (59.7)            0.62
    Yes                                                              15 (19.5)                 5 (33.3)                   10 (66.7)            
  Tumor stage                                                                                                                                  
    T2                                                               32 (35.6)                 16 (50.0)                  16 (50.0)            0.076
    ≥T3                                                              58 (64.4)                 18 (31.0)                  40 (69.0)            
  Lymph node status^[e](#tfn24-ol-0-0-10706){ref-type="table-fn"}^                                                                             
    N−                                                               35 (55.6)                 14 (40.0)                  21 (60.0)            0.52
    N+                                                               28 (44.4)                 9 (32.1)                   19 (67.9)            
  Phenotype^[f](#tfn25-ol-0-0-10706){ref-type="table-fn"}^                                                                                     
    Basal                                                            26 (30.6)                 16 (61.5)                  10 (38.5)            0.0025
    Non-basal                                                        59 (69.4)                 16 (27.1)                  43 (72.9)            

χ^2^ test.

Data available for 85 patients

data available for 83 patients

data available for 77 patients

data available for 63 patients

data available for 85 patients. *PLEKHS1*, pleckstrin homology domain-containing S1; MIBC, muscle-invasive bladder cancer.

###### 

Association of clincopathological variables and *PLEKHS1* mRNA level with NMIBC from the first series.

  Characteristic     Total population, n (%)   *PLEKHS1* mRNA no overexpression, n (%)   *PLEKHS1* mRNA overexpression, n (%)   P-value^[a](#tfn26-ol-0-0-10706){ref-type="table-fn"}^
  ------------------ ------------------------- ----------------------------------------- -------------------------------------- --------------------------------------------------------
  Total              71 (100)                  55 (77.5)                                 16 (22.5)                              
  Age                                                                                                                           
    ≥60              56 (78.9)                 43 (76.8)                                 13 (23.2)                              0.79
    \<60             15 (21.1)                 12 (80.0)                                 3 (20.0)                               
  Sex                                                                                                                           
    Male             63 (88.7)                 48 (76.2)                                 15 (23.8)                              0.79
    Female           8 (11.3)                  7 (87.5)                                  1 (12.5)                               
  Smoking status                                                                                                                
    Non-smoker       33 (46.5)                 25 (75.8)                                 8 (24.2)                               0.75
    Smoker           38 (53.5)                 30 (78.9)                                 8 (21.1)                               
  History of NMIBC                                                                                                              
    No               39 (54.9)                 31 (79.5)                                 8 (20.5)                               0.65
    Yes              32 (45.1)                 24 (75.0)                                 8 (25.0)                               
  Associated pTis                                                                                                               
    No               69 (97.2)                 54 (78.3)                                 15 (21.7)                              0.35
    Yes              2 (2.8)                   1 (50.0)                                  1 (50.0)                               
  Grade                                                                                                                         
    Low              25 (35.2)                 21 (84.0)                                 4 (16.0)                               0.33
    High             46 (64.8)                 34 (73.9)                                 12 (26.1)                              
  Tumor stage                                                                                                                   
    pTa              42 (59.2)                 35 (83.3)                                 7 (16.7)                               0.15
    pT1              29 (40.8)                 20 (69.0)                                 9 (31.0)                               

χ^2^ test. *PLEKHS1*, pleckstrin homology domain-containing S1; NMIBC, non-muscle-invasive bladder cancer.

###### 

Association of clinicopathological variables and *PLEKHS1* mRNA level with MIBC from the first series.

  Characteristic     Total population, n (%)   *PLEKHS1* mRNA no overexpression, n (%)   *PLEKHS1* mRNA overexpression, n (%)   P-value^[a](#tfn27-ol-0-0-10706){ref-type="table-fn"}^
  ------------------ ------------------------- ----------------------------------------- -------------------------------------- --------------------------------------------------------
  Total              83 (100)                  60 (72.3)                                 23 (27.7)                              
  Age                                                                                                                           
    ≥60              61 (73.5)                 44 (72.1)                                 17 (27.9)                              0.96
    \<60             22 (26.5)                 16 (72.7)                                 6 (27.3)                               
  Sex                                                                                                                           
    Male             66 (79.5)                 45 (68.2)                                 21 (31.8)                              0.10
    Female           17 (20.5)                 15 (88.2)                                 2 (11.8)                               
  Smoking status                                                                                                                
    Non-smoker       34 (41.0)                 23 (67.6)                                 11 (32.4)                              0.43
    Smoker           49 (59.0)                 37 (75.5)                                 12 (24.5)                              
  History of NMIBC                                                                                                              
    No               59 (71.1)                 39 (66.1)                                 20 (33.9)                              0.05
    Yes              24 (28.9)                 21 (87.5)                                 3 (12.5)                               
  Associated pTis                                                                                                               
    No               73 (88.0)                 52 (71.2)                                 21 (28.7)                              0.56
    Yes              10 (12.0)                 8 (80.0)                                  2 (20.0)                               
  Grade                                                                                                                         
    Low              34 (41.0)                 25 (73.5)                                 9 (26.5)                               0.83
    High             49 (59.0)                 35 (71.4)                                 14 (28.6)                              
  Tumor stage                                                                                                                   
    pTa              58 (69.9)                 39 (68.4)                                 19 (32.8)                              0.12
    pT1              25 (30.1)                 21 (84.0)                                 4 (16.0)                               

χ^2^ test. *PLEKHS1*, pleckstrin homology domain-containing S1; NMIBC, non-muscle-invasive bladder cancer.

###### 

Cox proportional-hazards regression analysis of factors affecting progression-free survival with non-muscle-invasive bladder cancer.

                             Progression-free survival                   
  -------------------------- --------------------------- --------------- -------
  T stage                    3.92                        (0.79--19.36)   0.093
  Grade                      2.19                        (0.20--24.58)   0.52
  *PLEKHS1* overexpression   4.01                        (1.11--14.50)   0.034

*PLEKHS1*, pleckstrin homology domain-containing S1; HR, hazard ratio.
